Obama’s Health Plan Could be Hijacked by Industry Which Sees Good Business
The Washington Post suggests, the chance for success in overhauling US healthcare depends on President Obama's ability to keep the major–discordant–players on board.
Supreme Court Rules Against Pharma Preemption
U.S. Supreme Court has ruled against Wyeth (and by extension, the pharmaceutical industry) which claimed immunity from liability for its failure warn about adverse drug effects by invoking FDA preemption
Sen. Grassley to Pfizer: Provide Details of $$ to Harvard MedicalFaculty
Sen. Charles Grassley sent a letter to Pfizer asking the company to provide details of its payments to at least 149 faculty members at Harvard Medical School.
US Device Mfg Sues UK Cardiologist for Truth Telling
Since 2006, the results of a multi-site clinical trial (MIST) that tested a surgical device have been at the center of dispute among cardiologists on both sides of the Atlantic.
RE: Stimulus Funding to Compare Treatments_Scientific American
AHRP Quoted in Scientific American
Marcia Angell: Drug Co & Doctors: A Story of Corruption
"It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine." Marcia Angell, MD
Grassley Probes COI at American Psychiatric Association
Sen. Grassley is peeling away psychiatry’s layers of deception about the efficacy and safety of its treatments: "I have come to understand that money from the pharmaceutical industry can shape the practices of nonprofit organizations that purport to be independent in their viewpoints and actions."
Letter of Complaint Re: FDA Double Agent
A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels.
Letter of Complaint to FDA Commissioner, 2007
Complaint about a surge of FDA administrative approvals for expanded use of highly toxic antipsychotic drugs for children. Approvals were determined by Dr. Thomas Laughren after secret deliberations–without disclosure of scientific data, without an advisory panel or open public discussion.
Non-profit Fronts for Drug Industry_Boston Globe
These paid lobbying efforts on behalf of industry are carried out under the pretext of advocacy in the public interest.
Medical Prostitution: Doctors On the Take–Minnesota an example, NYT
Minnesota is the first of a handful of states to pass a law requiring drug manufacturers to disclose payments to doctors.
The Damaging Impact of PDUFA and Why It Should be Repealed
The re-prioritization of rapid approvals occurred at the expense of drug safety standards,